OBJECTIVE: To estimate the prevalence of arthritis and arthritis pain exacerbations in US workers including impact on functioning and lost productive work time (LPT). METHODS: The research was conducted as a nested case-control study of participants in the Caremark American Productivity Audit, a US national random-digit-dial survey of US workers. The sample included 329 workers ages 40-65 years meeting the First National Health and Nutrition Examination Survey criteria for arthritis, and 91 workers not meeting arthritis inclusion criteria. Participants completed a telephone interview to measure the prevalence of arthritis and pain exacerbations, LPT (in hours and dollars), functional disability using the Western Ontario and McMaster Universities Knee and Hip Osteoarthritis Index (WOMAC) and the Australian/Canadian Osteoarthritis Hand Index, and demographics. RESULTS: The prevalence of arthritis in US workers ages 40-65 years was 14.7% during the 2-week period. Pain exacerbation occurred among 38% of participants with arthritis. Workers with pain exacerbations were significantly more likely to have higher WOMAC scores (38.6 versus 29.6; P = 0.0041) and report arthritis-related LPT (24.4% versus 13.3%; P = 0.0118) than workers without exacerbations. Among those with LPT, average LPT did not differ (4.1 hours per week) between persons with and without exacerbations. The estimated annual LPT cost from arthritis in the US workforce was $7.11 billion, with 65.7% of this cost attributed to the 38% of workers with pain exacerbations. CONCLUSION: Workers with arthritis pain exacerbation account for a disproportionate share of the arthritis-related LPT cost. Stratifying workers for appropriate treatment management based on pain exacerbation status could significantly decrease arthritis-related LPT and offer employees and employers an effective return on health care use.
OBJECTIVE: To estimate the prevalence of arthritis and arthritis pain exacerbations in US workers including impact on functioning and lost productive work time (LPT). METHODS: The research was conducted as a nested case-control study of participants in the Caremark American Productivity Audit, a US national random-digit-dial survey of US workers. The sample included 329 workers ages 40-65 years meeting the First National Health and Nutrition Examination Survey criteria for arthritis, and 91 workers not meeting arthritis inclusion criteria. Participants completed a telephone interview to measure the prevalence of arthritis and pain exacerbations, LPT (in hours and dollars), functional disability using the Western Ontario and McMaster Universities Knee and Hip Osteoarthritis Index (WOMAC) and the Australian/Canadian Osteoarthritis Hand Index, and demographics. RESULTS: The prevalence of arthritis in US workers ages 40-65 years was 14.7% during the 2-week period. Pain exacerbation occurred among 38% of participants with arthritis. Workers with pain exacerbations were significantly more likely to have higher WOMAC scores (38.6 versus 29.6; P = 0.0041) and report arthritis-related LPT (24.4% versus 13.3%; P = 0.0118) than workers without exacerbations. Among those with LPT, average LPT did not differ (4.1 hours per week) between persons with and without exacerbations. The estimated annual LPT cost from arthritis in the US workforce was $7.11 billion, with 65.7% of this cost attributed to the 38% of workers with pain exacerbations. CONCLUSION: Workers with arthritis pain exacerbation account for a disproportionate share of the arthritis-related LPT cost. Stratifying workers for appropriate treatment management based on pain exacerbation status could significantly decrease arthritis-related LPT and offer employees and employers an effective return on health care use.
Authors: Alesia B Sadosky; Andrew G Bushmakin; Joseph C Cappelleri; David R Lionberger Journal: Arthritis Res Ther Date: 2010-08-25 Impact factor: 5.156
Authors: Goktug C Ozmen; Asim H Gazi; Sevda Gharehbaghi; Kristine L Richardson; Mohsen Safaei; Daniel C Whittingslow; Sampath Prahalad; Jennifer L Hunnicutt; John W Xerogeanes; Teresa K Snow; Omer T Inan Journal: Ann Biomed Eng Date: 2021-05-13 Impact factor: 3.934
Authors: Marco Dacosta Dibonaventura; Shaloo Gupta; Margaret McDonald; Alesia Sadosky; Dan Pettitt; Stuart Silverman Journal: Health Qual Life Outcomes Date: 2012-03-15 Impact factor: 3.186